Pediatric Study Plans Should Be Made Public, FDA’s Oncology Advisers Say

 
• By Sarah Karlin-Smith

The push for more transparency so researchers are not unnecessarily duplicating or competing for the same small pool of patients raises a problem that goes beyond the RACE Act, FDA officials said.

young boy in hospital holding teddy bear and IV pole
The cancer research community needs more visibility into FDA-required pediatric study plans, agency advisors said. • Source: Shutterstock

More from Clinical Trials

More from R&D